Semaglutide vs Tirzepatide
A long-acting GLP-1 receptor agonist engineered for once-weekly dosing. A dual GIP and GLP-1 receptor agonist — the first of the co-agonists. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Semaglutide | Tirzepatide | |
|---|---|---|
| Also known as | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Type | Analog | Analog |
| Evidence | Established | Established |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | GLP-1 receptor agonist (acylated peptide, 31 aa) | Dual GIP/GLP-1 receptor agonist (39 aa, acylated) |
| Receptor | GLP-1 receptor (GLP-1R) | GIP receptor + GLP-1 receptor |
| Molecular weight | ~4,113.6 Da | ~4,813.5 Da |
| Half-life | ||
| Based on | Glucagon-like peptide-1 | Glucose-dependent insulinotropic polypeptide |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Semaglutide and Tirzepatide?
- Semaglutide is an engineered analog based on Glucagon-like peptide-1; Tirzepatide is an engineered analog based on Glucose-dependent insulinotropic polypeptide. Semaglutide signals at GLP-1 receptor (GLP-1R); Tirzepatide signals at GIP receptor + GLP-1 receptor.
- How do the half-lives of Semaglutide and Tirzepatide compare?
- The reported circulating half-life of Semaglutide is ~7 days (~165 h); Tirzepatide is ~5 days (~120 h). These are reference values for the native or representative form — educational only, not dosing advice.
- Is Semaglutide the same as Ozempic?
- Ozempic, Wegovy, Rybelsus are brand names of Semaglutide. This comparison describes the molecules, not branded products.
Prefer the other order? Tirzepatide vs Semaglutide. Or open the interactive comparison tool to add more molecules.